This is a prospective , randomized , active-controlled , PROBE design study in 56 patients ( 57 9 years , 52 % men ) with mild-to-moderate hypertension and type 2 diabetes , with normal ejection fraction , randomized to either indapamide ( 1.5 mg Slow Release ( SR ) / day ) or hydrochlorothiazide ( 25 mg/d ) , added to quinapril ( 10-40 mg/d ) .